Cyclacel Pharmaceuticals (CYCC) Tumbles on Failed Tests

Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) shares fell 20.9% to $4.28. Cyclacel reported that its Phase 3 SEAMLESS study did not meet primary endpoint. Share volume was 385,000, compared to an all-day average of 151,000